Dr. Doris Staab is head of the cystic fibrosis outpatient clinic at the Pediatric Department specializing in pneumology and immunology at the Charité hospital in Berlin.
Cystic fibrosis is caused by a genetic defect and varies in severity between patients, depending on exactly where the gene is damaged. However, the disorder always reduces lung function and makes the airways susceptible to bacterial infections. Mainly Caucasian people from Europe, North America and Australia are affected. About 70,000 cystic fibrosis patients around the world depend on drugs, physiotherapy and inhalation therapy throughout their lives.
Help for young patients
Researchers at Bayer HealthCare have now developed a new means of treatment: Ciprofloxacin Inhale – an innovative formulation of Bayer’s proven antibiotic ciprofloxacin. The drug is inhaled directly into the lungs where it can combat bacterial pathogens. Read here to find out about how the method will make treatment easier, especially for young cystic fibrosis patients.